Company profile
Home - PhoreMost
Through its SITESEEKER drug target identification platform, PhoreMost is expanding druggable space. In partnership, we are discovering and developing the
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new 'druggable' target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel 'targeted' therapies more efficiently to market and pass these cost savings onto patients.
PhoreMost is developing technology for discovering targetable sites on cells or microbes that are involved in diseases have proved difficult to treat.
Advances in genomics and basic research are providing a long list of clear causes that lie at the heart of a range of debilitating diseases. This has the potential to open the door to many new and improved targeted therapies. However, many of these newly characterized disease targets are intractable to current drug discovery technologies. PhoreMost is aiming to remove these barriers to new drug development with its novel SITESEEKER technology, a live-cell phenotypic assay system that can rapidly identify unexpected, or "cryptic" druggable sites in specific disease driving targets and pathways that can't be readily seen using conventional non-cell based analytical methods. PhoreMost's first drug discovery program is based on a novel target that addresses the "undruggable" cancer gene KRAS, which affects multiple types of cancer. This program has recently completed lead optimisation and in vivo anti-tumour activity has been succesfully demonstrated. PhoreMost is now seeking partners for its further clinical development.
1 Jul 2017 to 31 Mar 2020
A new approach to cancer therapy called 'immuno-therapy' has recently emerged that is now providing unheralded responses in certain cancer types. It is based on the concept that as tumours arise through sequential mutations in their genomes, this also creates 'foreign' antigens that can be recognised and attacked by the immune system. However, tumours als...
1 May 2017 to 31 Mar 2019
The pharmaceutical industry makes medicines designed to reverse the things that go wrong in cells and cause disease. The list of the targets that go wrong is far from complete, and we do not have the screening tools to find and then develop drugs to these targets. To cope with an increasing healthcare need, we therefore need to expand that list and to mak...
1 Apr 2015 to 31 Mar 2017
Cancer is a genetic disease caused by mutations in key genes that regulate cell-growth and survival. In recent years, new ‘targeted’ therapies that aim to functionally reverse the root genetic causes of cancer have shown success in many cancer types. However Pancreatic tumours, a particularly lethal form of cancer, has not benefited from such advances; pr...
